COMP <GO>
MGX vs GNTA // EV/EBITDA & P/E VALUATION
Metagenomi Therapeutics Inc. (NASDAQ) VS. Genenta Science S.p.A. (NASDAQ) • 15-METRIC TALLY: MGX 2
— GNTA 0
■ METRIC PARITY
LAST: $0.83 (+1.03%) • MKT CAP: $31.4M
valuation
—
LAST: $0.62 (+2.48%) • MKT CAP: $29.9M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MGX VS. GNTA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MGX | GNTA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -51.80% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.1 | 36.5 | +18.55 | MGX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $31.4M | $29.9M | $1.5M | MGX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MGX REV | GNTA REV | MGX GROSS % | GNTA GROSS % | MGX FCF | GNTA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $25.2M | — | — | — | -$89.5M | — |
| FY 2024 | $52.3M | — | — | — | -$112.2M | — |
| FY 2023 | $44.8M | — | — | — | -$91.4M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MGX // BETA —
GNTA // BETA —